Results 121 to 130 of about 1,577 (196)

Combinatorial treatment with upadacitinib abrogates systemic toxicity of a tumor-targeted IL-2 fusion protein. [PDF]

J Immunother Cancer
Rotta G, Prodi E, Seehusen F, Bocci M, Prisco F, Gilardoni E, Comacchio C, Halin C, Puca E, Neri D, Dakhel Plaza S.   +10 more
europepmc   +1 more source

Increased Peripheral T Stem Cell-like Memory Features in Patients with Advanced Solid Tumors Treated with Tumor-Targeting IL-12 Immunocytokine Therapy. [PDF]

Clin Cancer Res
Goswami M, Celades C, Minnar CM, Khelifa AS, Poppe LK, Bracken-Clarke D, Toney NJ, Lynch MT, Marté JL, Gameiro SR, Gulley JL, Schlom J, Donahue RN.   +12 more
europepmc   +1 more source

In vitro detection of canine anti-human antibodies following intratumoral injection of the hu14.18-IL2 immunocytokine in spontaneous canine melanoma. [PDF]

PLoS One
Kosharek AT, Zuleger CL, Glass WS, Eickhoff J, Sondel PM, Vail DM, Albertini MR.   +6 more
europepmc   +1 more source

The quadruple immunotherapy for colorectal cancer (QuICC) trial for mismatch repair-proficient metastatic colorectal cancer. [PDF]

Oncologist
Bracken-Clarke D, Pastor DM, Marté JL, Donahue RN, Hodge JW, Cordes L, Floudas CS, Tschernia NP, Karzai F, Brownell I, Turkbey EB, Soon-Shiong P, Schlom J, Gulley JL, Maeng HM, Strauss J, Redman JM.   +16 more
europepmc   +1 more source

Supplementary Video 1 from Combining Adoptive Cellular and Immunocytokine Therapies to Improve Treatment of B-Lineage Malignancy

, 2023
Stephen J. Forman, Andrew Raubitschek, Laurence J.N. Cooper, Timothy Pfeiffer, Harjeet Singh, Zaid Al-Kadhimi, Michael C. Jensen, David D. Smith, David Colcher, George McNamara, Simon Olivares, Lisa Marie Serrano, Stephen D. Gillies   +12 more
core   +1 more source

1159 A targeted masked ImmunoCytokine for CD138 expressing cancers

Journal for ImmunoTherapy of Cancer, 2023
Ryan Trinh, Alex Vasuthasawat, Sherie L Morrison, David Stover   +3 more
doaj   +1 more source

Universal Fab-Fc masked cytokine prodrug platform: αPD-L1/IL-15 prodrug activates CD44⁺ CD8⁺ T cells in tumor-draining lymph nodes to enhance antitumor immunity. [PDF]

J Immunother Cancer
Song L, Qi G, Shi W, Zeng Q, Qin Y, Wang Z, Li W, Song Z, Zhang A, Lu H.   +9 more
europepmc   +1 more source

An engineered Treg selective immunocytokine induces sustained immune modulation in a preclinical model of hemophilia A. [PDF]

J Thromb Haemost
Rana J, VanDyke D, Muñoz-Melero M, Fabilane CS, Thirumurugan S, Arisa S, Zhou B, Spangler JB, Biswas M.   +8 more
europepmc   +1 more source

Immunocytokine NHS-IL2-LT [PDF]

, 2020
openaire   +1 more source

TIGIT-targeted IL-12 fusion protein engages NK and CD8⁺ T cells for potent tumor immunotherapy. [PDF]

Cell Rep Med
Tang M, Huang Y, Bi J, Meng D, Zheng X, Peng H, Sun R, Ma H, Tian Z, Sun H, Zheng X.   +10 more
europepmc   +1 more source